Our industry-leading compound collection features over 3 million high-quality small molecules, derived from big pharma legacy collections. This diverse and novel chemical space, with 80% unique structures, is unmatched by other commercial libraries. Every compound is documented in our life science database (LSDB), containing over 500 million data points for swift decision-making during hit selection. Our novel Nuvisan explorer library, focusing on lead-like compounds, streamlines the optimisation process for targeted drug discovery. With 340,000 non-proprietary compounds, it offers a cost-effective hit-finding solution.